The treatment of acute myeloid leukaemia (AML):
1. Anthracycline (Daunorubicin or Idarubicin) +
2. Cytarabine +/ - Gemtuzumab Ozogamicin
Patients with secondary AML should recieve a liposomal formulation of Cytarabine or Daunorubicin available as Xyxeos.
Patients with FLT3 mutation benefit from the addition of FLT3 kinase inhibitor midostaurin.
Old patients who may not tolerate chemotherapy may benefit from bcl2 inhibitor Venetoclox + Cytarabine, enasidenib, ivosidenib, or glasdegib.
Treatment of ALL( acute lymphoblastic leukemia):
1. Daunorubicin +
2. Vincristine +
3. Prednisone +
4. Asparaginase
Patients positive for bcr-abl gene mutation should receive a tyrosine kinase inhibitor